Retatrutide 30mg UAE – Clinical Research & Product Information

Description

Retatrutide 30mg UAE is a product listing associated with retatrutide, an investigational compound being studied in clinical research. Retatrutide is also known by the development code LY3437943 and is being investigated as a triple hormone receptor agonist involving the GIP, GLP-1 and glucagon pathways.

The current Pureness X product page lists a 30 mg strength and a displayed price of AED 790. These are product-page details and may change; the live page should always be checked for current information.

Retatrutide has attracted considerable scientific interest because of its multi-receptor mechanism and ongoing clinical development. However, it is important to distinguish clinical research from regulatory approval. As of July 2026, Lilly states that retatrutide has not been approved by any regulatory agency and is not available for public use.

Quick Product Overview

The strength and price above are taken from the current Pureness X product listing.

What Is Retatrutide?

Retatrutide is an investigational molecule being developed by Eli Lilly. It is designed to activate three hormone receptor pathways:

• GIP receptor

• GLP-1 receptor

• Glucagon receptor

Because it acts across all three pathways, retatrutide is commonly described as a triple agonist or triple hormone receptor agonist.

This mechanism is one of the main reasons retatrutide has become an important subject in obesity and metabolic-health research.

Unlike a GLP-1-only approach, retatrutide is being investigated for the combined effects of GLP-1, GIP and glucagon receptor activity.

How Does the Triple-Agonist Approach Work?

The three receptor pathways have different biological roles.

GLP-1

GLP-1 signalling is involved in appetite, satiety and glucose regulation.

GIP

GIP is involved in glucose-dependent insulin signalling and metabolic processes.

Glucagon

Glucagon plays an important role in energy metabolism and regulation of stored energy.

Researchers are investigating whether activating these pathways together can produce meaningful changes in body weight and metabolic outcomes.

Why Is Retatrutide Being Studied?

Retatrutide has attracted attention because of its multi-pathway mechanism.

Clinical research has examined outcomes such as:

• Body-weight change

• Body composition

• Metabolic markers

• Glucose-related outcomes

• Appetite-related effects

• Safety and tolerability

In the published Phase 2 obesity trial, retatrutide produced substantial reductions in body weight over 48 weeks compared with placebo. The study also reported gastrointestinal adverse events as the most common adverse events.

These results come from controlled clinical research and should not be interpreted as guaranteed results for an individual.

Retatrutide Clinical Research

Retatrutide has progressed into large Phase 3 clinical-development programs.

In 2026, Lilly reported Phase 3 results from several studies, including trials involving obesity, overweight with type 2 diabetes, and obesity with cardiovascular disease. Lilly also states that retatrutide remains investigational and is not yet approved for public use.

Current development areas include obesity and several obesity-related conditions. The research program is designed to evaluate both potential efficacy and safety in larger patient populations.

Clinical trials are particularly important for determining:

• Whether research findings are reproducible

• How different populations respond

• The safety profile

• Common and serious adverse events

• Longer-term outcomes

• Appropriate regulatory standards

Retatrutide and Weight-Loss Research

Weight management is one of the most prominent areas of retatrutide research.

A Phase 2 randomized clinical trial published in the New England Journal of Medicine evaluated retatrutide in adults with obesity. Participants receiving retatrutide experienced substantial average reductions in body weight over 48 weeks, with greater reductions observed at higher studied doses. Gastrointestinal adverse events were among the most common reported events.

More recent Phase 3 research has continued to evaluate retatrutide in larger populations. Lilly reported positive topline results from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 during 2026, although detailed peer-reviewed publications for some newer results may follow separately.

Research outcomes should always be considered in the context of the specific study design, population, duration and investigational protocol.

Retatrutide 30mg Product Information

The Pureness X page currently lists this product as Retatrutide 30 with a stated strength of 30 mg and a price of AED 790.

For an online research-product listing, users should independently verify:

• Product identity

• Manufacturer or supplier information

• Batch or lot details

• Certificate of Analysis where applicable

• Laboratory documentation

• Storage and handling information

• Regulatory status

• Intended research use

A product listing by itself does not establish that a compound is an approved medicine or that its contents meet clinical-drug standards.

Retatrutide UAE: Regulatory Considerations

People searching for Retatrutide 30mg UAE should pay particular attention to regulatory status.

According to Lilly's July 2026 information, retatrutide is still an investigational molecule, has not been approved by a regulatory agency, and is not available for public use. Lilly specifically warns against products claiming to contain retatrutide outside its clinical-trial system because their ingredients, purity and amount of active compound cannot be reliably verified.

Therefore:

Online availability does not equal regulatory approval.

Clinical-trial research does not equal approval for consumer use.

A product listing does not establish clinical safety or authenticity.

Anyone researching regulatory requirements in the UAE should verify the current requirements with the relevant UAE health authority.

Retatrutide Safety Research

Safety is an important component of the ongoing retatrutide development program.

In the published Phase 2 obesity study, gastrointestinal adverse events were common and generally mild to moderate. The study also reported dose-dependent increases in heart rate that peaked around week 24 and declined afterward.

Because the compound remains under investigation, its full long-term safety profile is still being evaluated.

For this reason, an online product page should not provide individualized dosing or injection instructions. Medical decisions involving investigational compounds belong within appropriate clinical and regulatory frameworks.

Retatrutide vs GLP-1 Research

Retatrutide is sometimes compared with GLP-1-based therapies because one of its three receptor targets is GLP-1.

However, the mechanisms are different.

Retatrutide's three-pathway mechanism is the central scientific feature that distinguishes it from single-pathway approaches.

Mechanism alone, however, does not establish that one treatment is better or safer than another.

Retatrutide and LY3437943

LY3437943 is the development code used for retatrutide.

When researching scientific publications or clinical-trial information, both terms can be useful:

• Retatrutide

• LY3437943

Using the development code can help users locate clinical-trial records and scientific literature that may not use the commercial research name in their titles.

What Does “Triple Agonist” Mean?

The term triple agonist describes retatrutide's activity across three receptor pathways:

GIP + GLP-1 + glucagon

This mechanism is being studied because these pathways are involved in appetite regulation, glucose metabolism and energy balance.

The term “triple agonist” is more scientifically appropriate than informal labels such as “GLP-3,” which Lilly notes is not an accurate scientific classification.

What Should You Verify About a Research Product?

Before relying on any online research-product listing, verify the information that is relevant to the product and its intended use.

Product Identity

Confirm the compound name, stated strength and labeling.

Documentation

Look for available batch, lot and laboratory documentation.

Certificate of Analysis

Where applicable, review a batch-specific Certificate of Analysis rather than relying only on a generic certificate.

Storage Information

Verify the supplier's stated storage requirements and handling procedures.

Supplier Information

Check the identity and reputation of the supplier and whether claims can be independently verified.

Regulatory Status

Confirm the current regulatory position before making decisions involving an investigational compound.

Frequently Asked Questions

What is Retatrutide 30mg?

Retatrutide 30 is a product listing for a stated 30 mg strength of retatrutide. Retatrutide itself is an investigational triple hormone receptor agonist studied in clinical trials.

What is LY3437943?

LY3437943 is the development code associated with retatrutide.

Is retatrutide a GLP-1-only compound?

No. Retatrutide is being investigated as a triple agonist involving GLP-1, GIP and glucagon receptors.

Is retatrutide approved?

No. As of July 2026, Lilly states that retatrutide has not been approved by any regulatory agency and remains investigational.

Is retatrutide available for public use?

Lilly currently states that retatrutide is not available for public use and is being studied in clinical trials.

What is the price listed on this page?

The Pureness X page currently displays AED 790 for Retatrutide 30. Product pricing can change, so the live page should be checked for the current price.

What is retatrutide being studied for?

Clinical development includes obesity and several related conditions. Lilly's current Phase 3 program includes obesity, type 2 diabetes and other obesity-related conditions.

Final Thoughts

Retatrutide has become an important topic in metabolic-health research because it is being investigated as a GIP, GLP-1 and glucagon triple receptor agonist.

Clinical research has shown substantial effects on body weight in studied populations, while newer Phase 3 trials continue to evaluate its potential benefits and safety across broader populations.

For readers researching Retatrutide 30mg UAE, the most important distinction is between a product listing and an approved medicine. Retatrutide remains investigational and is not currently approved for public use.

Medical & Regulatory Disclaimer

This page is provided for educational and research-information purposes only. Retatrutide is an investigational compound and is not currently approved for general public use.

This content does not provide medical advice, diagnosis, individualized dosing or treatment recommendations. Product availability on an online store does not establish regulatory approval, authenticity, purity, safety or suitability for human use.

Always verify current UAE regulatory requirements and consult a qualified healthcare professional for medical questions.